Image-guided radiation therapy vendor ViewRay reported in its preliminary results a growth in total revenue of roughly 8% for its fiscal 2019 (end-December 31, 2019), despite a large drop in orders in its fourth quarter.
For the fiscal year, ViewRay expects total revenue to be approximately $88 million, up roughly 8% from $81 million in 2018. Total revenue is expected to reach approximately $17 million in the fourth quarter, down from $21 million in the same quarter the previous year. There were only four new orders for MRIdian systems in the fourth quarter of 2019, compared with eight new orders in the same quarter of the prior year.
ViewRay also said that its chief commercial officer, Jim Alecxih, is set to leave the company effective January 17.
